Serplulimab Evidence: Trial Results and Peer-Reviewed Publications
Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:
The clinical evidence base for Serplulimab comprises 38 peer-reviewed publications across 15 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Stomach Neoplasms, Uterine Cervical Neoplasms, Small Cell Lung Carcinoma, and Esophageal Squamous Cell Carcinoma. Most recent publication: Neoadjuvant immunochemotherapy plus thymalfasin in locally advanced gastric cancer: a prospective clinical trial., BMC Med, 2026.
Top peer-reviewed publications
Curated set of pivotal-trial result papers and recent publications in high-tier journals.
- Lineage tracking reveals dynamic relationships of T cells in colorectal cancer.Zhang L, Yu X, Zheng L, et al. · Nature · 2019
- Gastric cancer.Van Cutsem E, Sagaert X, Topal B, et al. · Lancet · 2017
- Helicobacter pylori infection and the development of gastric cancer.Uemura N, Okamoto S, Yamamoto S, et al. · N Engl J Med · 2001
- Gastric cancer.Smyth EC, Nilsson M, Grabsch HI, et al. · Lancet · 2020
- Programmed cell death-1 inhibition in lymphoma.Hawkes EA, Grigg A, Chong G, et al. · Lancet Oncol · 2015
- B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.Dong H, Zhu G, Tamada K, et al. · Nat Med · 1999
- Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4).Boku N, Ryu MH, Kato K, et al. · Ann Oncol · 2020
- Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.Bang YJ, Kang YK, Catenacci DV, et al. · Gastric Cancer · 2019
Publications by year
1999–2026: 38 publications.
1999
1
2001
1
2003
1
2004
1
2005
1
2011
1
2012
2
2013
1
2014
2
2015
2
2016
4
2017
4
2018
3
2019
3
2020
2
2021
1
2022
1
2023
1
2024
2
2025
1
2026
3
Publications by indication
Stomach Neoplasms (25)
- Neoadjuvant immunochemotherapy plus thymalfasin in locally advanced gastric cancer: a prospective clinical trial.
- Gastric cancer.
- Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4).
- Lineage tracking reveals dynamic relationships of T cells in colorectal cancer.
- Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.
Uterine Cervical Neoplasms (5)
- New Strategies for Multimodality Therapy in Treating Locally Advanced Cervix Cancer.
- Concurrent chemoradiotherapy for cervical cancer: background including evidence-based data, pitfalls of the data, limitation of treatment in certain groups.
- Changing paradigms in the systemic treatment of advanced cervical cancer.
- Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study.
- Cervical cancer.
Small Cell Lung Carcinoma (2)
- Rationale and Design of a Phase II Trial of Combined Serplulimab and Chemotherapy in Patients with Histologically Transformed Small Cell Lung Cancer: a Prospective, Single-arm and Multicentre Study.
- Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial.
Esophageal Squamous Cell Carcinoma (1)
- Neoadjuvant serplulimab combined with chemotherapy for resectable oesophageal squamous cell carcinoma: a single-arm, phase 2 trial.
Carcinoma, Non-Small-Cell Lung (1)
- Simplified perioperative serplulimab and chemotherapy for resectable squamous NSCLC: a phase II trial with biomarker analysis.
Publications by journal
- Cell3 papers
- Lancet3 papers
- Nature2 papers
- J Clin Oncol2 papers
- N Engl J Med1 paper
- Cancer Immunol Immunother1 paper
- Br J Cancer1 paper
- Int J Cancer1 paper
- Prev Med1 paper
- Cancer Treat Rev1 paper
All Serplulimab publications (38)
2026 (3 papers)
- Neoadjuvant immunochemotherapy plus thymalfasin in locally advanced gastric cancer: a prospective clinical trial.Xu H, Li F, Li B, et al. · BMC Med · 2026 · Derived
- Neoadjuvant serplulimab combined with chemotherapy for resectable oesophageal squamous cell carcinoma: a single-arm, phase 2 trial.Wu Z, Wu C, Wang Y, et al. · Nat Commun · 2026 · Derived
- Simplified perioperative serplulimab and chemotherapy for resectable squamous NSCLC: a phase II trial with biomarker analysis.Fu F, Wu H, Deng C, et al. · J Immunother Cancer · 2026 · Derived
2025 (1 paper)
- Nuclear to Cytoplasmic Transport Is a Druggable Dependency in HDAC7-driven Small Cell Lung Cancer.Qin T, Wang J, Wang J, et al. · Adv Sci (Weinh) · 2025 · Background
2024 (2 papers)
- Study protocol of short-course radiotherapy combined with CAPOX and PD-1 inhibitor for locally advanced colon cancer: a randomised, prospective, multicentre, phase II trial (TORCH-C).Zhang H, Li Y, Xia F, et al. · BMJ Open · 2024 · Derived
- Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies.Liu Q, Zhang J, Guo C, et al. · Cell · 2024 · Background
2023 (1 paper)
- Rationale and Design of a Phase II Trial of Combined Serplulimab and Chemotherapy in Patients with Histologically Transformed Small Cell Lung Cancer: a Prospective, Single-arm and Multicentre Study.Huang J, Zhang XH, Cai Y, et al. · Clin Oncol (R Coll Radiol) · 2023 · Derived
2022 (1 paper)
- Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial.Cheng Y, Han L, Wu L, et al. · JAMA · 2022 · Background
2021 (1 paper)
- XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a.Wang J, Sun T, Meng Z, et al. · Cancer Lett · 2021 · Background
2020 (2 papers)
- Gastric cancer.Smyth EC, Nilsson M, Grabsch HI, et al. · Lancet · 2020 · Trial result
- Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4).Boku N, Ryu MH, Kato K, et al. · Ann Oncol · 2020 · Trial result
2019 (3 papers)
- Lineage tracking reveals dynamic relationships of T cells in colorectal cancer.Zhang L, Yu X, Zheng L, et al. · Nature · 2019 · Trial result
- Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.Bang YJ, Kang YK, Catenacci DV, et al. · Gastric Cancer · 2019 · Trial result
- Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment.Azizi E, Carr AJ, Plitas G, et al. · Cell · 2019 · Trial result
2018 (3 papers)
- Management of Helicobacter Pylori in the United States: Results from a national survey of gastroenterology physicians.Murakami TT, Scranton RA, Brown HE, et al. · Prev Med · 2018 · Trial result
- Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: A meta-analysis.Li Z, Shan F, Wang Y, et al. · PLoS One · 2018 · Trial result
- New Strategies for Multimodality Therapy in Treating Locally Advanced Cervix Cancer.Verma J, Monk BJ, Wolfson AH, et al. · Semin Radiat Oncol · 2018 · Background
2017 (4 papers)
- Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing.Zheng C, Zheng L, Yoo JK, et al. · Cell · 2017 · Trial result
- Gastric cancer.Van Cutsem E, Sagaert X, Topal B, et al. · Lancet · 2017 · Trial result
- Phase II Study of Neoadjuvant Chemotherapy With S-1 and CDDP in Patients With Lymph Node Metastatic Stage II or III Gastric Cancer.Kochi M, Fujii M, Kanamori N, et al. · Am J Clin Oncol · 2017 · Trial result
- Elements of cancer immunity and the cancer-immune set point.Chen DS, Mellman I · Nature · 2017 · Trial result
2016 (4 papers)
- PD-1 and PD-L1 blockade in gastrointestinal malignancies.Lote H, Cafferkey C, Chau I, et al. · Cancer Treat Rev · 2016 · Trial result
- Cancer statistics in China, 2015.Chen W, Zheng R, Baade PD, et al. · CA Cancer J Clin · 2016 · Trial result
- Concurrent chemoradiotherapy for cervical cancer: background including evidence-based data, pitfalls of the data, limitation of treatment in certain groups.Todo Y, Watari H · Chin J Cancer Res · 2016 · Background
- Changing paradigms in the systemic treatment of advanced cervical cancer.Pfaendler KS, Tewari KS · Am J Obstet Gynecol · 2016 · Background
2015 (2 papers)
- Global burden of gastric cancer attributable to Helicobacter pylori.Plummer M, Franceschi S, Vignat J, et al. · Int J Cancer · 2015 · Trial result
- Programmed cell death-1 inhibition in lymphoma.Hawkes EA, Grigg A, Chong G, et al. · Lancet Oncol · 2015 · Trial result
2014 (2 papers)
- PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients.Sun S, Fei X, Mao Y, et al. · Cancer Immunol Immunother · 2014 · Trial result
- Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention.Karimi P, Islami F, Anandasabapathy S, et al. · Cancer Epidemiol Biomarkers Prev · 2014 · Trial result
2013 (1 paper)
- Defining surgical quality in gastric cancer: a RAND/UCLA appropriateness study.Brar S, Law C, McLeod R, et al. · J Am Coll Surg · 2013 · Trial result
2012 (2 papers)
- Neoadjuvant chemotherapy with FOLFOX: improved outcomes in Chinese patients with locally advanced gastric cancer.Li ZY, Koh CE, Bu ZD, et al. · J Surg Oncol · 2012 · Trial result
- [Efficacy and safety of SOX regimen as neoadjuvant chemotherapy for advanced gastric cancer].Li T, Chen L · Zhonghua Wei Chang Wai Ke Za Zhi · 2012 · Trial result
2011 (1 paper)
- Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.Ychou M, Boige V, Pignon JP, et al. · J Clin Oncol · 2011 · Trial result
2005 (1 paper)
- Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF.Sumpter K, Harper-Wynne C, Cunningham D, et al. · Br J Cancer · 2005 · Trial result
2004 (1 paper)
- Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study.Moore DH, Blessing JA, McQuellon RP, et al. · J Clin Oncol · 2004 · Background
2003 (1 paper)
- Cervical cancer.Waggoner SE · Lancet · 2003 · Background
2001 (1 paper)
- Helicobacter pylori infection and the development of gastric cancer.Uemura N, Okamoto S, Yamamoto S, et al. · N Engl J Med · 2001 · Trial result
1999 (1 paper)
- B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.Dong H, Zhu G, Tamada K, et al. · Nat Med · 1999 · Trial result
Sources and methodology
- Publications:
ctgov.study_references(PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference typesRESULT,DERIVED, andBACKGROUND. - Per-arm outcome values:
ctgov.outcome_measurementsjoined toctgov.design_outcomeswhereoutcome_type = 'PRIMARY', restricted to phasePHASE3andPHASE2/PHASE3. - Publication metadata (title, journal, year, authors): PubMed E-utilities
efetch.fcgi - Data freshness: Tue, 02 Jun 2026 16:48:21 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).